The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1234
May 8, 2006
View Complete Issue         Table of Contents 2019 
Invader UGT1A1 Molecular Assay for Irinotecan Toxicity
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Invader UGT1A1 Molecular Assay for Irinotecan Toxicity
May 8, 2006 (Issue: 1234)
The FDA has approved a new genetic test to identify patients who may be at increased risk of severe toxicity when treated with the cancer chemotherapy drug irinotecan (Camptosar). The Invader UGT1A1 Molecular Assay (Third Wave Technologies) detects...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Invader UGT1A1 Molecular Assay for Irinotecan Toxicity
Article code: 1234c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.